Eribulin treatment was found to increase the population of bladder-tumor-infiltrating NK cells (Figure 1B) as well as markers of their activation (NKG2D), degranulation (CD107a), and tissue residency (CD49a and CD103) compared to vehicle-treated control mice (Figure 1C–F) [4,8,19]. This evidence concerns the gene KLRK1 and urinary bladder neoplasm.